Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Psychiatria
MENU
Na skróty Zdeponuj artykuł Wytyczne dla autorów Ahead of print Recenzenci 2022 Kolegium redakcyjne

Tom 19, Nr 3 (2022)
Artykuł przeglądowy
Opublikowany online: 2021-12-27
Dodaj do koszyka: 49,00 PLN
Pobierz cytowanie

May application of oxytocin be relevant in the therapy of perinatal mental disorders?

Miłosz Gołyszny1, Magdalena Durańska2, Oliwia Korzonek2, Michał Zieliński1, Ewa Obuchowicz1
DOI: 10.5603/PSYCH.a2021.0048
·
Psychiatria 2022;19(3):214-226.
Afiliacje
  1. Department of Pharmacology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland
  2. Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland

dostęp płatny

Tom 19, Nr 3 (2022)
Artykuły przeglądowe
Opublikowany online: 2021-12-27

Streszczenie

The perinatal period is a time, when mental diseases occur more frequently, than in other stages of life. Treatment of postpartum depression, psychosis, anxiety is a very hard task. Many psychotropic drugs display a toxic potential during the perinatal period. Hence, it seems that, searching for an alternative pharmacotherapy is relevant. Oxytocin is a substance, that may be successfully used in gynecological treatment. However, its potential is definitely greater. Studies from recent years indicated, that oxytocin is involved in complex pathomechanism of affective disorders. Latest outcomes indicate, that intranasal administration of oxytocin is effective in the treatment of anxiety- and depressive behaviors. The aim of the study is based on the question: Is oxytocin relevant for mental disorders in perinatal period therapy? This question was posed in order to gain psychiatric knowledge about perinatal period’s mental problems and indicates putative novel therapeutic solutions. The research team has performed a review of the studies, searching well-known online scientific databases, including PubMed, ScienceDirect, Scopus and MedLine. Our findings shed light on oxytocin’s significance in a potential new therapy of perinatal mental disorders. Further studies should be focused on intranasal oxytocin administration and its effectivity in the treatment of mentioned diseases, adverse effects, pharmacovigilance, pharmacokinetics and pharmacodynamics. Still, scarce data from clinical studies do not allow the implementation of oxytocin in treatment of perinatal affective disturbances, despite of rationale psychobiological and pharmacological prerequisites. Hence, it is necessary to investigate the relation: oxytocin intervention — perinatal affective disorders.

Streszczenie

The perinatal period is a time, when mental diseases occur more frequently, than in other stages of life. Treatment of postpartum depression, psychosis, anxiety is a very hard task. Many psychotropic drugs display a toxic potential during the perinatal period. Hence, it seems that, searching for an alternative pharmacotherapy is relevant. Oxytocin is a substance, that may be successfully used in gynecological treatment. However, its potential is definitely greater. Studies from recent years indicated, that oxytocin is involved in complex pathomechanism of affective disorders. Latest outcomes indicate, that intranasal administration of oxytocin is effective in the treatment of anxiety- and depressive behaviors. The aim of the study is based on the question: Is oxytocin relevant for mental disorders in perinatal period therapy? This question was posed in order to gain psychiatric knowledge about perinatal period’s mental problems and indicates putative novel therapeutic solutions. The research team has performed a review of the studies, searching well-known online scientific databases, including PubMed, ScienceDirect, Scopus and MedLine. Our findings shed light on oxytocin’s significance in a potential new therapy of perinatal mental disorders. Further studies should be focused on intranasal oxytocin administration and its effectivity in the treatment of mentioned diseases, adverse effects, pharmacovigilance, pharmacokinetics and pharmacodynamics. Still, scarce data from clinical studies do not allow the implementation of oxytocin in treatment of perinatal affective disturbances, despite of rationale psychobiological and pharmacological prerequisites. Hence, it is necessary to investigate the relation: oxytocin intervention — perinatal affective disorders.

Pełny tekst:

Dodaj do koszyka: 49,00 PLN
Pobierz cytowanie

Słowa kluczowe

perinatal mental diseases, oxytocin, psychiatric gynecology

Informacje o artykule
Tytuł

May application of oxytocin be relevant in the therapy of perinatal mental disorders?

Czasopismo

Psychiatria

Numer

Tom 19, Nr 3 (2022)

Typ artykułu

Artykuł przeglądowy

Strony

214-226

Opublikowany online

2021-12-27

Wyświetlenia strony

3228

Wyświetlenia/pobrania artykułu

117

DOI

10.5603/PSYCH.a2021.0048

Rekord bibliograficzny

Psychiatria 2022;19(3):214-226.

Słowa kluczowe

perinatal mental diseases
oxytocin
psychiatric gynecology

Autorzy

Miłosz Gołyszny
Magdalena Durańska
Oliwia Korzonek
Michał Zieliński
Ewa Obuchowicz

Referencje (164)
  1. Müldner-Nieckowski L, Cyranka K, Smiatek-Mazgaj B, et al. Multiaxial changes in pregnancy: mental health--a review of the literature. Ginekol Pol. 2014; 85(10): 784–787.
    PubMed
  2. Koszewska IO. O depresji w ciąży i po porodzie. Wydawnictwo Lekarskie PZWL, Warszawa 2010.
  3. Su M. Baby blues and postnatal depression in low risk mothers. Hong Kong J Gynaecol Obstet Midwifery. 2000; 1: 40-46.
  4. Gewin V. Baby blues. Nature. 2005; 433(7027): 780–781.
    CrossRefPubMed
  5. Fromm E. Modern man’s pathology of normalcy. Pathology of normalcy. Lantern Books, New York 2011.
  6. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psych. 1994; 151(10): 1409–1416.
    CrossRef
  7. Vajda FJE, O'Brien TJ, Graham J, et al. Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand. 2013; 128(4): 228–234.
    CrossRefPubMed
  8. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007; 356(26): 2675–2683.
    CrossRefPubMed
  9. Marcus SM. Depression during pregnancy: rates, risks and consequences--Motherisk Update 2008. Can J Clin Pharmacol. 2009; 16(1): e15–e22.
    PubMed
  10. Mulder EJH, Robles de Medina PG, Huizink AC, et al. Prenatal maternal stress: effects on pregnancy and the (unborn) child. Early Hum Dev. 2002; 70(1-2): 3–14.
    CrossRefPubMed
  11. Bosquet M, Egeland B. Associations among maternal depressive symptomatology, state of mind and parent and child behaviors: implications for attachment-based interventions. Attach Hum Dev. 2001; 3(2): 173–199.
    CrossRefPubMed
  12. Medved S, Bajs JanoviĆ M, Štimac Z, et al. Add-on Oxytocin in the Treatment of Postpartum Acute Schizophrenia: A Case Report. J Psychiatr Pract. 2021; 27(4): 326–332.
    CrossRefPubMed
  13. Ellenbogen M, Cardoso C, Serravalle L, et al. T142. Intranasal Oxytocin Augments the Efficacy of Psychotherapy for Major Depressive Disorder. Biological Psychiatry. 2018; 83(9): S183.
    CrossRef
  14. Ozsoy S, Olguner Eker O, Abdulrezzak U. The Effects of Antidepressants on Neuropeptide Y in Patients with Depression and Anxiety. Pharmacopsychiatry. 2016; 49(1): 26–31.
    CrossRefPubMed
  15. Scantamburlo G, Hansenne M, Geenen V, et al. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial. Eur Psychiatry. 2015; 30(1): 65–68.
    CrossRefPubMed
  16. Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010; 68(7): 678–680.
    CrossRefPubMed
  17. Misri S. Suffering in silence: the burden of perinatal depression. Can J Psychiatry. 2007; 52(8): 477–478.
    CrossRefPubMed
  18. Dudek D, Siwek M, Zieba A, Nowak G. Postpartum depression. Prz Lek. 2002; 59(11): 919-923.
  19. Maina G, Albert U, Bogetto F, et al. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res. 1999; 89(1): 49–58.
    CrossRefPubMed
  20. Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum period: A systematic review. J Clin Psychiatry. 2006; 67(8): 1285–1298.
    CrossRefPubMed
  21. Reck C, Stehle E, Reinig K, et al. Maternity blues as a predictor of DSM-IV depression and anxiety disorders in the first three months postpartum. J Affect Disord. 2009; 113(1-2): 77–87.
    CrossRefPubMed
  22. Pop VJM, Truijens SEM, Spek V, et al. A new concept of maternity blues: Is there a subgroup of women with rapid cycling mood symptoms? J Affect Disord. 2015; 177: 74–79.
    CrossRefPubMed
  23. Rezaie-Keikhaie K, Arbabshastan ME, Rafiemanesh H, et al. Systematic Review and Meta-Analysis of the Prevalence of the Maternity Blues in the Postpartum Period. J Obstet Gynecol Neonatal Nurs. 2020; 49(2): 127–136.
    CrossRefPubMed
  24. Seyfried LS, Marcus SM. Postpartum mood disorders. Int Rev Psychiatry. 2003; 15(3): 231–242.
    CrossRefPubMed
  25. Reroń A, Gierat B, Huras H. Ocena częstotliwości występowania depresji poporodowej. Gin Prakt. 2004; 12(3): 32–35.
  26. Łojko D, Suwalska A, Rybakowski J. Dwubiegunowe zaburzenia nastroju i zaburzenia depresyjne w klasyfikacji DSM-5. Psychiatr Pol. 2014; 48(2): 245–260.
  27. World Health Organization. The WHO application of ICD-10 to deaths during pregnancy, childbirth and puerperium: ICD-MM. World Health Organization. 2012.
  28. Sharma V, Khan M. Identification of bipolar disorder in women with postpartum depression. Bipolar Disord. 2010; 12(3): 335–340.
    CrossRefPubMed
  29. O'Hara MW. Postpartum depression: what we know. J Clin Psychol. 2009; 65(12): 1258–1269.
    CrossRefPubMed
  30. Nieland M, Roger D. Symptoms in post-partum and non-post-partum samples: Implications for postnatal depression. Journal of Reproductive and Infant Psychology. 1997; 15(1): 31–42.
    CrossRef
  31. Mauri M, Banti S, Borri C, et al. P02-387 - Depressive symptomatology in pregnancy detected with EPDS: the problem of false positive. European Psychiatry. 2010; 25: 1403.
    CrossRef
  32. Le Strat Y, Dubertret C, Le Foll B. Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. J Affect Disord. 2011; 135(1-3): 128–138.
    CrossRefPubMed
  33. Silva R, Jansen K, Souza L, et al. Sociodemographic risk factors of perinatal depression: a cohort study in the public health care system. Braz J Psychiatry. 2012; 34(2): 143–148.
    CrossRefPubMed
  34. Silverman ME, Smith L, Lichtenstein P, et al. The risk factors for postpartum depression: A population-based study. Depress Anxiety. 2017; 34(2): 178–187.
    CrossRefPubMed
  35. Mavrogiorgou P, Illes F, Juckel G. [Perinatal obsessive-compulsive disorder]. Fortschr Neurol Psychiatr. 2011; 79(9): 507–516.
    CrossRefPubMed
  36. Spinelli MG. Postpartum psychosis: detection of risk and management. Am J Psychiatry. 2009; 166(4): 405–408.
    CrossRefPubMed
  37. Newman L, Judd F, Olsson CA, et al. Early origins of mental disorder - risk factors in the perinatal and infant period. BMC Psychiatry. 2016; 16: 270.
    CrossRefPubMed
  38. Bergink V, Bouvy PF, Vervoort JSP, et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry. 2012; 169(6): 609–615.
    CrossRefPubMed
  39. Heron J, Craddock N, Jones I. Postnatal euphoria: are 'the highs' an indicator of bipolarity? Bipolar Disord. 2005; 7(2): 103–110.
    CrossRefPubMed
  40. Sharma V, Burt VK. DSM-V: modifying the postpartum-onset specifier to include hypomania. Arch Womens Ment Health. 2011; 14(1): 67–69.
    CrossRefPubMed
  41. Sharma V, Corpse C. Is your depressed postpartum patient bipolar? Curr Psychiatry. 2011; 10(6): 81–83.
  42. Smith S, Heron J, Haque S, et al. Measuring hypomania in the postpartum: a comparison of the Highs Scale and the Altman Mania Rating Scale. Arch Womens Ment Health. 2009; 12(5): 323–327.
    CrossRefPubMed
  43. Stuart S, Koleva H. Psychological treatments for perinatal depression. Best Pract Res Clin Obstet Gynaecol. 2014; 28(1): 61–70.
    CrossRefPubMed
  44. Craske M. Cognitive-behavioral therapy. Psychotherapy theories and techniques: A reader. 2014: 79–86.
    CrossRef
  45. O'Hara MW, Stuart S, Gorman LL, et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry. 2000; 57(11): 1039–1045.
    CrossRefPubMed
  46. Lipsitz JD, Markowitz JC. Mechanisms of change in interpersonal therapy (IPT). Clin Psychol Rev. 2013; 33(8): 1134–1147.
    CrossRefPubMed
  47. Gebuza G, Jaworska K, Mieczkowska E, et al. The breastfeeding after natural birth and by caesarean section. Pediatr Pol. 2015; 95(5): 384–390.
  48. Krzyżanowska–Zbucka J. Okołoporodowe zaburzenia psychiczne a krzywdzenie dzieci. Dziecko Krzywdzone. Teoria, badania, praktyka. 2010; 9(3): 44–53.
  49. ESCOP Monographs, The Scientific Foundation for Herbal Medicinal Products. Exeter: ESCOP, Stuttgart, New York: Thieme, 2003.
  50. Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep. 2010; 12(2): 96–103.
    CrossRefPubMed
  51. Yonkers KA, Blackwell KA, Glover J, et al. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014; 10: 369–392.
    CrossRefPubMed
  52. Ornoy A, Weinstein-Fudim L, Ergaz Z. Antidepressants, Antipsychotics, and Mood Stabilizers in Pregnancy: What Do We Know and How Should We Treat Pregnant Women with Depression. Birth Defects Res. 2017; 109(12): 933–956.
    CrossRefPubMed
  53. Rai D, Lee BK, Dalman C, et al. Antidepressants during pregnancy and autism in offspring: population based cohort study. BMJ. 2017; 358: j2811.
    CrossRefPubMed
  54. Payne JL. Psychopharmacology in Pregnancy and Breastfeeding. Med Clin North Am. 2019; 103(4): 629–650.
    CrossRefPubMed
  55. Kronenfeld N, Ziv Baran T, Berlin M, et al. Chronic use of psychotropic medications in breastfeeding women: Is it safe? PLoS One. 2018; 13(5): e0197196.
    CrossRefPubMed
  56. Emmelkamp PM, Beens H. Cognitive therapy with obsessive-compulsive disorder: a comparative evaluation. Behav Res Ther. 1991; 29(3): 293–300.
    CrossRefPubMed
  57. March J, Mulle K. Manualized cognitive-behavioral psychotherapy for obsessive-compulsive disorder in childhood: A preliminary single case study. Journal of Anxiety Disorders. 1995; 9(2): 175–184.
    CrossRef
  58. March JS, Franklin M, Nelson A, Foa E. Cognitive-behavioral psychotherapy for pediatric obsessive-compulsive disorder. J Clin Child Adolesc Psychol. 2001; 30(1): 8-18.
  59. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017; 317(13): 1358–1367.
    CrossRefPubMed
  60. National Collaborating Centre for Mental Health UK. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. British Psychological Society. 2006.
  61. Kumar R. Postnatal mental illness: a transcultural perspective. Soc Psychiatry Psychiatr Epidemiol. 1994; 29(6): 250–264.
    CrossRefPubMed
  62. Godet PF, Marie-Cardine M. [Neuroleptics, schizophrenia and pregnancy. Epidemiological and teratologic study]. Encephale. 1991; 17(6): 543–547.
    PubMed
  63. Stanton J, Simpson A. Filicide: a review. Int J Law Psychiatry. 2002; 25(1): 1–14.
    CrossRefPubMed
  64. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005; 66(4): 444–9; quiz 546.
    CrossRefPubMed
  65. Huybrechts KF, Hernandez-Diaz S, Straub L, et al. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry. 2016; 73(9): 938–946.
    CrossRefPubMed
  66. Tomson T, Battino D, Tomson T, et al. [Malformations in the offspring of pregnant women with epilepsy. Presentation of an international registry of antiepileptic drugs and pregnancy (EURAP)]. Rev Neurol. 2002; 34(5): 476–480.
    PubMed
  67. Shallcross R, Bromley RL, Irwin B, et al. Liverpool Manchester Neurodevelopment Group, UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011; 76(4): 383–389.
    CrossRefPubMed
  68. Rinaman L, Sherman TG, Stricker EM. Vasopressin and oxytocin in the central nervous system. Psychopharmacology: The fourth generation of progress. 1995: 531-542.
  69. Crowley WR, Armstrong WE. Neurochemical regulation of oxytocin secretion in lactation. Endocr Rev. 1992; 13(1): 33–65.
    CrossRefPubMed
  70. Blanks AM, Thornton S. The role of oxytocin in parturition. BJOG. 2003; 110 Suppl 20: 46–51.
    CrossRefPubMed
  71. Evans JJ, Reid RA, Wakeman SA, et al. Evidence that oxytocin is a physiological component of LH regulation in non-pregnant women. Hum Reprod. 2003; 18(7): 1428–1431.
    CrossRefPubMed
  72. Lui C, Cui Xg, Wang Yx, et al. Association between neuropeptide oxytocin and male infertility. J Assist Reprod Genet. 2010; 27(9-10): 525–531.
    CrossRefPubMed
  73. Crespi BJ. Oxytocin, testosterone, and human social cognition. Biol Rev Camb Philos Soc. 2016; 91(2): 390–408.
    CrossRefPubMed
  74. Ding C, Magkos F. Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspectives. Curr Obes Rep. 2019; 8(3): 301–316.
    CrossRefPubMed
  75. Leng G, Caquineau C, Sabatier N. Regulation of oxytocin secretion. Vitam Horm. 2005; 71: 27–58.
    CrossRefPubMed
  76. Caligioni CS, Oliver C, Jamur MC, et al. Presence of oxytocin receptors in the gonadotrophin-releasing hormone (GnRH) neurones in female rats: a possible direct action of oxytocin on GnRH neurones. J Neuroendocrinol. 2007; 19(6): 439–448.
    CrossRefPubMed
  77. Salehi MS, Khazali H, Mahmoudi F, et al. Oxytocin Intranasal Administration Affects Neural Networks Upstream of GNRH Neurons. J Mol Neurosci. 2017; 62(3-4): 356–362.
    CrossRefPubMed
  78. Ivell R, Furuya K, Brackmann B, et al. Expression of the oxytocin and vasopressin genes in human and baboon gonadal tissues. Endocrinology. 1990; 127(6): 2990–2996.
    CrossRefPubMed
  79. Argiolas A. Oxytocin stimulation of penile erection. Pharmacology, site, and mechanism of action. Ann N Y Acad Sci. 1992; 652: 194–203.
    CrossRefPubMed
  80. Melis MR, Stancampiano R, Argiolas A, et al. Oxytocin-induced penile erection and yawning: site of action in the brain. Brain Res. 1986; 398(2): 259–265.
    CrossRefPubMed
  81. Frayne J, Townsend D, Nicholson HD. Effects of oxytocin on sperm transport in the pubertal rat. J Reprod Fertil. 1996; 107(2): 299–306.
    CrossRefPubMed
  82. Robinson DA, Wei F, Wang GD, et al. Oxytocin mediates stress-induced analgesia in adult mice. J Physiol. 2002; 540(Pt 2): 593–606.
    CrossRefPubMed
  83. Jahromi BN, Dabbaghmanesh MH, Bakhshaie P, et al. Assessment of oxytocin level, glucose metabolism components and cutoff values for oxytocin and anti-mullerian hormone in infertile PCOS women. Taiwan J Obstet Gynecol. 2018; 57(4): 555–559.
    CrossRefPubMed
  84. Gołyszny M. “Stare” i “nowe” neuropeptydy jako modulatory czynności osi stresu. Psychiatria. 2018; 2(5): 409–422.
  85. Schneiderman I, Kanat-Maymon Y, Zagoory-Sharon O, et al. Mutual influences between partners' hormones shape conflict dialog and relationship duration at the initiation of romantic love. Soc Neurosci. 2014; 9(4): 337–351.
    CrossRefPubMed
  86. Bosch OJ, Dabrowska J, Modi ME, et al. Oxytocin in the nucleus accumbens shell reverses CRFR2-evoked passive stress-coping after partner loss in monogamous male prairie voles. Psychoneuroendocrinology. 2016; 64: 66–78.
    CrossRefPubMed
  87. Lee HJ, Macbeth AH, Pagani JH, et al. Oxytocin: the great facilitator of life. Prog Neurobiol. 2009; 88(2): 127–151.
    CrossRefPubMed
  88. Nagasawa M, Okabe S, Mogi K, et al. Oxytocin and mutual communication in mother-infant bonding. Front Hum Neurosci. 2012; 6: 31.
    CrossRefPubMed
  89. Odent M, Odent M. New reasons and new ways to study birth physiology. Int J Gynaecol Obstet. 2001; 75 Suppl 1: S39–S45.
    CrossRefPubMed
  90. Matthiesen AS, Ransjö-Arvidson AB, Nissen E, et al. Postpartum maternal oxytocin release by newborns: effects of infant hand massage and sucking. Birth. 2001; 28(1): 13–19.
    CrossRefPubMed
  91. Gottschalk MG, Domschke K. Oxytocin and Anxiety Disorders. Curr Top Behav Neurosci. 2018; 35: 467–498.
    CrossRefPubMed
  92. Windle RJ, Shanks N, Lightman SL, et al. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology. 1997; 138(7): 2829–2834.
    CrossRefPubMed
  93. Ditzen B, Schaer M, Gabriel B, et al. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry. 2009; 65(9): 728–731.
    CrossRefPubMed
  94. De Groot AN, Vree TB, Hekster YA, et al. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. J Pharm Pharmacol. 1995; 47(7): 571–575.
    CrossRefPubMed
  95. Cegieła U, Folwarczna J, Janiec R, Janiec W, Kaczmarczyk-Sedlak IH, Nowińska BE. Kompendium farmakologii. Wydawnictwo Lekarskie PZWL, Warszawa 2017.
  96. Leake RD, Weitzman RE, Fisher DA. Pharmacokinetics of oxytocin in the human subject. Obstet Gynecol. 1980; 56(6): 701–704.
    PubMed
  97. Ruis H, Rolland R, Doesburg W, et al. Oxytocin enhances onset of lactation among mothers delivering prematurely. Br Med J (Clin Res Ed). 1981; 283(6287): 340–342.
    CrossRefPubMed
  98. Gutkowska J, Jankowski M. Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol. 2012; 24(4): 599–608.
    CrossRefPubMed
  99. Aldana-Valenzuela C, Prieto-Pantoja JA, Hernández-Acevedo A. [Oxytocin and syndrome of inappropriate secretion of antidiuretic neonatal hormone. Case report of early severe hyponatremia and literature review]. Ginecol Obstet Mex. 2010; 78(12): 692–696.
    PubMed
  100. Sweeney G, Holbrook AM, Levine M, et al. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. Curr Ther Res Clinl Experiment. 1990; 47(3): 528–540.
  101. Hofmann SG, Fang A, Brager DN, et al. RETRACTED: Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies. Psychiatry Res. 2015; 228(3): 708–714.
    CrossRefPubMed
  102. Leng G, Ludwig M. Intranasal Oxytocin: Myths and Delusions. Biol Psychiatry. 2016; 79(3): 243–250.
    CrossRefPubMed
  103. Evans SL, Dal Monte O, Noble P, et al. Intranasal oxytocin effects on social cognition: a critique. Brain Res. 2014; 1580: 69–77.
    CrossRefPubMed
  104. Heinrichs M, Baumgartner T, Kirschbaum C, et al. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry. 2003; 54(12): 1389–1398.
    CrossRefPubMed
  105. Baumgartner T, Heinrichs M, Vonlanthen A, et al. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron. 2008; 58(4): 639–650.
    CrossRefPubMed
  106. Guastella AJ, Mitchell PB, Mathews F. Oxytocin enhances the encoding of positive social memories in humans. Biol Psychiatry. 2008; 64(3): 256–258.
    CrossRefPubMed
  107. Petrovic P, Kalisch R, Singer T, et al. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci. 2008; 28(26): 6607–6615.
    CrossRefPubMed
  108. Arletti R, Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci. 1987; 41(14): 1725–1730.
    CrossRefPubMed
  109. Grund T, Goyon S, Li Y, et al. Neuropeptide S Activates Paraventricular Oxytocin Neurons to Induce Anxiolysis. J Neurosci. 2017; 37(50): 12214–12225.
    CrossRefPubMed
  110. Waldherr M, Neumann ID. Centrally released oxytocin mediates mating-induced anxiolysis in male rats. Proc Natl Acad Sci U S A. 2007; 104(42): 16681–16684.
    CrossRefPubMed
  111. Gołyszny M, Obuchowicz E. Are neuropeptides relevant for the mechanism of action of SSRIs? Neuropeptides. 2019; 75: 1–17.
    CrossRefPubMed
  112. Uvnäs-Moberg K, Bjökstrand E, Hillegaart V, et al. Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacology (Berl). 1999; 142(1): 95–101.
    CrossRefPubMed
  113. Olff M, Langeland W, Witteveen A, et al. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectr. 2010; 15(8): 522–530.
    CrossRefPubMed
  114. Koch SBj, van Zuiden M, Nawijn L, et al. Intranasal Oxytocin Administration Dampens Amygdala Reactivity towards Emotional Faces in Male and Female PTSD Patients. Neuropsychopharmacology. 2016; 41(6): 1495–1504.
    CrossRefPubMed
  115. van Zuiden M, Frijling JL, Nawijn L, et al. Intranasal Oxytocin to Prevent Posttraumatic Stress Disorder Symptoms: A Randomized Controlled Trial in Emergency Department Patients. Biol Psychiatry. 2017; 81(12): 1030–1040.
    CrossRefPubMed
  116. Sack M, Spieler D, Wizelman L, et al. Intranasal oxytocin reduces provoked symptoms in female patients with posttraumatic stress disorder despite exerting sympathomimetic and positive chronotropic effects in a randomized controlled trial. BMC Med. 2017; 15(1): 40.
    CrossRefPubMed
  117. Guastella AJ, Howard AL, Dadds MR, et al. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009; 34(6): 917–923.
    CrossRefPubMed
  118. Labuschagne I, Phan KL, Wood A, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology. 2010; 35(12): 2403–2413.
    CrossRefPubMed
  119. Ansseau M, Legros JJ, Mormont C, et al. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology. 1987; 12(3): 231–236.
    CrossRefPubMed
  120. Boer Jd, Westenberg H. Oxytocin in obsessive compulsive disorder. Peptides. 1992; 13(6): 1083–1085.
    CrossRef
  121. Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry. 1996; 40(6): 547–549.
    CrossRefPubMed
  122. Marazziti D, Baroni S, Giannaccini G, et al. Plasma Oxytocin Levels in Untreated Adult Obsessive-Compulsive Disorder Patients. Neuropsychobiology. 2015; 72(2): 74–80.
    CrossRefPubMed
  123. Bujanow W. Letter: Is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J. 1974; 19(3): 323.
    CrossRefPubMed
  124. Souza RP, Ismail P, Meltzer HY, et al. Variants in the oxytocin gene and risk for schizophrenia. Schizophr Res. 2010; 121(1-3): 279–280.
    CrossRefPubMed
  125. Shilling PD, Feifel D. Potential of Oxytocin in the Treatment of Schizophrenia. CNS Drugs. 2016; 30(3): 193–208.
    CrossRefPubMed
  126. Averbeck BB, Bobin T, Evans S, et al. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med. 2012; 42(2): 259–266.
    CrossRefPubMed
  127. Goldman MB, Gomes AM, Carter CS, et al. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (Berl). 2011; 216(1): 101–110.
    CrossRefPubMed
  128. Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011; 132(1): 50–53.
    CrossRefPubMed
  129. Modabbernia A, Rezaei F, Salehi B, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs. 2013; 27(1): 57–65.
    CrossRefPubMed
  130. Clarici A, Pellizzoni S, Guaschino S, et al. Intranasal adminsitration of oxytocin in postnatal depression: implications for psychodynamic psychotherapy from a randomized double-blind pilot study. Front Psychol. 2015; 6: 426.
    CrossRefPubMed
  131. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010; 67(7): 692–694.
    CrossRefPubMed
  132. Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012; 3(1): 16.
    CrossRefPubMed
  133. Hall SS, Lightbody AA, McCarthy BE, et al. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012; 37(4): 509–518.
    CrossRefPubMed
  134. Skrundz M, Bolten M, Nast I, et al. Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology. 2011; 36(9): 1886–1893.
    CrossRefPubMed
  135. Higuchi T, Kaba H. Neuromodulatory role of oxytocin in the control of maternal behavior. Neural control of reproduction: Physiology and behavior. New York: S. Karger AG; 1997.
  136. Pedersen CA, Vadlamudi SV, Boccia ML, et al. Maternal behavior deficits in nulliparous oxytocin knockout mice. Genes Brain Behav. 2006; 5(3): 274–281.
    CrossRefPubMed
  137. Nelson EE, Panksepp J. Brain substrates of infant-mother attachment: contributions of opioids, oxytocin, and norepinephrine. Neurosci Biobehav Rev. 1998; 22(3): 437–452.
    CrossRefPubMed
  138. Gordon I, Zagoory-Sharon O, Leckman JF, et al. Oxytocin and the development of parenting in humans. Biol Psychiatry. 2010; 68(4): 377–382.
    CrossRefPubMed
  139. Da Costa AP, Guevara-Guzman RG, Ohkura S, et al. The role of oxytocin release in the paraventricular nucleus in the control of maternal behaviour in the sheep. J Neuroendocrinol. 1996; 8(3): 163–177.
    CrossRefPubMed
  140. Pryce CR, Martin RD. Motherhood in Human and Non-human Primates, Biosocial Determinants. Basel: Karger; 1995.
  141. Debiec J. Peptides of love and fear: vasopressin and oxytocin modulate the integration of information in the amygdala. Bioessays. 2005; 27(9): 869–873.
    CrossRefPubMed
  142. Uvnäs-Moberg K. Antistress pattern induced by oxytocin. News in Physiological Sciences. 1998; 13(1): 22-25.
  143. Brummelte S, Galea LAM. Postpartum depression: Etiology, treatment and consequences for maternal care. Horm Behav. 2016; 77: 153-166.
  144. Ehlert U, Patalla U, Kirschbaum C, et al. Postpartum blues: salivary cortisol and psychological factors. J Psychosom Res. 1990; 34(3): 319–325.
    CrossRefPubMed
  145. Uvnäs-Moberg U. Oxytocin, das Hormon der Nähe: Gesundheit–Wohlbefinden-Beziehung. Berlin: Springer-Verlag; 2016.
  146. Cummiskey KC, Dawood MY. Induction of labor with pulsatile oxytocin. Am J Obstet Gynecol. 1990; 163(6 Pt 1): 1868–1874.
    CrossRefPubMed
  147. Moura D, Canavarro MC, Figueiredo-Braga M. Oxytocin and depression in the perinatal period-a systematic review. Arch Womens Ment Health. 2016; 19(4): 561–570.
    CrossRefPubMed
  148. Strathearn L. Maternal neglect: oxytocin, dopamine and the neurobiology of attachment. J Neuroendocrinol. 2011; 23(11): 1054–1065.
    CrossRefPubMed
  149. Bell AF, Carter CS, Steer CD, et al. Interaction between oxytocin receptor DNA methylation and genotype is associated with risk of postpartum depression in women without depression in pregnancy. Front Genet. 2015; 6: 243.
    CrossRefPubMed
  150. Kimmel M, Clive M, Gispen F, et al. Oxytocin receptor DNA methylation in postpartum depression. Psychoneuroendocrinology. 2016; 69: 150–160.
    CrossRefPubMed
  151. Jonas W, Mileva-Seitz V, Girard AW, et al. MAVAN Research Team. Genetic variation in oxytocin rs2740210 and early adversity associated with postpartum depression and breastfeeding duration. Genes Brain Behav. 2013; 12(7): 681–694.
    CrossRefPubMed
  152. Lara-Cinisomo S, McKenney K, Di Florio A, et al. Associations Between Postpartum Depression, Breastfeeding, and Oxytocin Levels in Latina Mothers. Breastfeed Med. 2017; 12(7): 436–442.
    CrossRefPubMed
  153. Kroll-Desrosiers AR, Nephew BC, Babb JA, et al. Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year. Depress Anxiety. 2017; 34(2): 137–146.
    CrossRefPubMed
  154. Figueiredo B, Canário C, Field T. Breastfeeding is negatively affected by prenatal depression and reduces postpartum depression. Psychol Med. 2014; 44(5): 927–936.
    CrossRefPubMed
  155. Stuebe AM, Grewen K, Meltzer-Brody S. Association between maternal mood and oxytocin response to breastfeeding. J Womens Health (Larchmt). 2013; 22(4): 352–361.
    CrossRefPubMed
  156. Wang T, Shi C, Li X, et al. Injection of oxytocin into paraventricular nucleus reverses depressive-like behaviors in the postpartum depression rat model. Behav Brain Res. 2018; 336: 236–243.
    CrossRefPubMed
  157. Ji H, Su W, Zhou R, et al. Intranasal oxytocin administration improves depression-like behaviors in adult rats that experienced neonatal maternal deprivation. Behav Pharmacol. 2016; 27(8): 689–696.
    CrossRefPubMed
  158. Mah BL, Van Ijzendoorn MH, Smith R, et al. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40: 267–272.
    CrossRefPubMed
  159. Mah BL, Van Ijzendoorn MH, Out D, et al. The Effects of Intranasal Oxytocin Administration on Sensitive Caregiving in Mothers with Postnatal Depression. Child Psychiatry Hum Dev. 2017; 48(2): 308–315.
    CrossRefPubMed
  160. Donadon MF, Martin-Santos R, L Osório F. Oxytocin effects on the cognition of women with postpartum depression: A randomized, placebo-controlled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2021; 111: 110098.
    CrossRefPubMed
  161. De Cagna F, Fusar-Poli L, Damiani S, et al. The Role of Intranasal Oxytocin in Anxiety and Depressive Disorders: A Systematic Review of Randomized Controlled Trials. Clin Psychopharmacol Neurosci. 2019; 17(1): 1–11.
    CrossRefPubMed
  162. Badr HA, Zauszniewski JA. Kangaroo care and postpartum depression: The role of oxytocin. Int J Nurs Sci. 2017; 4(2): 179–183.
    CrossRefPubMed
  163. Uvnäs-Moberg K. The oxytocin factor: Tapping the hormone of calm, love, and healing. Cambridge: Da Capo Press; 2003.
  164. Thul TA, Corwin EJ, Carlson NS, et al. Oxytocin and postpartum depression: A systematic review. Psychoneuroendocrinology. 2020; 120: 104793.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl